Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in an inflammation model of depression

European Journal of Pharmacology

Volumn 793, Issue , 2016, Pages 21-27

  Yao, Wei ^a   Zhang, Ji Chun ^a   Ishima, Tamaki ^a   Ren, Qian ^a   Yang, Chun ^a   Dong, Chao ^a   Ma, Min ^a   Saito, Akira ^b   Honda, Tadashi ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Antidepressant; Inflammation; MCE 1; Neurite outgrowth; Nrf2; TBE 31

Indexed keywords

ANTIDEPRESSANT AGENT; LIPOPOLYSACCHARIDE; MCE 1; SMALL INTERFERING RNA; TBE 31; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 3-ETHYNYL-3-METHYL-6-OXOCYCLOHEXA-1,4-DIENECARBONITRILE; CYCLOHEXANONE DERIVATIVE; NERVE GROWTH FACTOR; NFE2L2 PROTEIN, RAT; PHENANTHRENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DRUG STRUCTURE; FORCED SWIM TEST; INFLAMMATION; LOCOMOTION; MALE; MOUSE; NERVE FIBER GROWTH; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; TAIL SUSPENSION TEST; ANIMAL; ANIMAL BEHAVIOR; BLOOD; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NEURITE OUTGROWTH; PATHOLOGY; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CYCLOHEXANONES; DEPRESSION; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; NERVE GROWTH FACTOR; NEURONAL OUTGROWTH; NF-E2-RELATED FACTOR 2; PC12 CELLS; PHENANTHRENES; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85000461123     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.10.037     Document Type: Article

References (45)

1. Chen, H., Wu, J., Zhang, J., Fujita, Y., Ishima, T., Iyo, M., Hashimoto, K., Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology 222 (2012), 37–45.
2. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
3. Dinkova-Kostova, A.T., Talalay, P., Sharkey, J., Zhang, Y., Holtzclaw, W.D., Wang, X.J., David, E., Schiavoni, K.H., Finlayson, S., Mierke, D.F., Honda, T., An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. J. Biol. Chem. 285 (2010), 33747–33755.
4. Dong, C., Zhang, J.C., Yao, W., Ren, Q., Yang, C., Ma, M., Han, M., Saito, R., Hashimoto, K., Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 144 (2016), 7–12.
5. Hashimoto, K., Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 61 (2009), 105–123.
6. Hashimoto, K., Inflammatory biomarkers as differential predictors of antidepressant response. Int. J. Mol. Sci. 16 (2015), 7796–7801.
7. Hashimoto, K., Ishima, T., A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation factor eIF4AI. PLoS One, 5, 2010, e15430.
8. Honda, T., Sundararajan, C., Yoshizawa, H., Su, X., Honda, Y., Liby, K.T., Sporn, M.B., Gribble, G.W., Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents. J. Med. Chem. 50 (2007), 1731–1734.
9. Honda, T., Yoshizawa, H., Sundararajan, C., David, E., Lajoie, M.J., Favaloro, F.G. Jr, Janosik, T., Su, X., Honda, Y., Roebuck, B.D., Gribble, G.W., Tricyclic compounds containing nonenolizable cyano enones: a novel class of highly potent anti-inflammatory and cytoprotective agents. J. Med. Chem. 54 (2011), 1762–1778.
10. Innamorato, N.G., Rojo, A.I., Garcia-Yague, A.J., Yamamoto, M., de Ceballos, M.L., Cuadrado, A., The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 181 (2008), 680–689.
11. Ishima, T., Iyo, M., Hashimoto, K., Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole. Transl. Psychiatry, 2, 2012, e170.
12. Ishima, T., Futamura, T., Ohgi, Y., Yoshimi, N., Kikuchi, T., Hashimoto, K., Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1Aand 5-HT2Areceptors. Eur. Neuropsychopharmacol. 25 (2015), 505–511.
13. Kobayashi, E., Suzuki, T., Yamamoto, M., Roles nrf2 plays in myeloid cells and related disorders. Oxid. Med. Cell. Longev., 2013, 2013, 529219.
14. Kostov, R.V., Knatko, E.V., McLaughlin, L.A., Henderson, C.J., Zheng, S., Huang, J.T., Honda, T., Dinkova-Kostova, A.T., Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. Biochem. Biophys. Res. Commun. 465 (2015), 402–407.
15. Lee, J.M., Johnson, J.A., An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 37 (2004), 139–143.
16. Liby, K., Yore, M.M., Roebuck, B.D., Baumgartner, K.J., Honda, T., Sundararajan, C., Yoshizawa, H., Gribble, G.W., Williams, C.R., Risingsong, R., Royce, D.B., Dinkova-Kostova, A.T., Stephenson, K.K., Egner, P.A., Yates, M.S., Groopman, J.D., Kensler, T.W., Sporn, M.B., A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res. 68 (2008), 6727–6733.
17. Lu, X.H., Dwyer, D.S., Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J. Mol. Neurosci. 27 (2005), 43–64.
18. Ma, M., Ren, Q., Zhang, J.C., Hashimoto, K., Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration. Clin. Psychopharmacol. Neurosci. 12 (2014), 31–36.
19. Ma, Q., Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 401–426.
20. Ma, Q., He, X.Q., Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2. Pharmacol. Rev. 64 (2012), 1055–1081.
21. Martín-de-Saavedra, M.D., Budni, J., Cunha, M.P., Gómez-Rangel, V., Lorrio, S., Del Barrio, L., Lastres-Becker, I., Parada, E., Tordera, R.M., Rodrigues, A.L., Cuadrado, A., López, M.G., Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 38 (2013), 2010–2022.
22. Mendez-David, I., Tritschler, L., Ali, Z.E., Damiens, M.H., Pallardy, M., David, D.J., Kerdine-Römer, S., Gardier, A.M., Nrf2-signaling and BDNF: a new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. Neurosci. Lett. 597 (2015), 121–126.
23. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65 (2009), 732–741.
24. O'Connell, M.A., Hayes, J.D., The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem. Soc. Trans. 43 (2015), 687–689.
25. O'Connor, J.C., Lawson, M.A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenaseactivation in mice. Mol. Psychiatry 14 (2009), 511–522.
26. Ohgi, Y., Futamura, T., Kikuchi, T., Hashimoto, K., Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 103 (2013), 856–859.
27. de Paiva, V.N., Lima, S.N., Fernandes, M.M., Soncini, R., Andrade, C.A., Giusti-Paiva, A., Prostaglandins mediate depressive-like behaviour induced by endotoxin in mice. Behav. Brain Res. 215 (2010), 146–151.
28. Raison, C.L., Lowry, C.A., Rook, G.A., Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch. Gen. Psychiatry 67 (2010), 1211–1224.
29. Shirai, Y., Fujita, Y., Hashimoto, K., Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. Clin. Psychopharmacol. Neurosci. 10 (2012), 97–98.
30. Shirai, Y., Fujita, Y., Hashimoto, R., Ohi, K., Yamamori, H., Yasuda, Y., Ishima, T., Suganuma, H., Ushida, Y., Takeda, M., Hashimoto, K., Dietary intake of sulforaphane-rich broccoli sprout extracts during Juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLoS One, 10, 2015, e0127244.
31. Spielmans, G.I., Berman, M.I., Linardatos, E., Rosenlicht, N.Z., Perry, A., Tsai, A.C., Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med., 10, 2013, e1001403.
32. Suzuki, T., Yamamoto, M., Molecular basis of the Keap1-Nrf2 system. Free Radic. Biol. Med. 88 (2015), 93–100.
33. Suzuki, T., Motohashi, H., Yamamoto, M., Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 34 (2013), 340–346.
34. Wardyn, J.D., Ponsford, A.H., Sanderson, C.M., Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochem. Soc. Trans. 43 (2015), 621–626.
35. Williams, B., Dwyer, D.S., Structure-based discovery of low molecular weight compounds that stimulate neurite outgrowth and substitute for nerve growth factor. J. Neurochem. 110 (2009), 1876–1884.
36. Yang, C., Hashimoto, K., Peripheral IL-6 signaling: a promising therapeutic target for depression?. Expert Opin. Investig. Drugs 24 (2015), 989–990.
37. Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Hashimoto, K., Peripheral interleukin-6 promotes resilience versus susceptibility to inescapable electric stress. Acta Neuropsychiatr. 27 (2015), 312–316.
38. Yao, W., Zhang, J.C., Dong, C., Zhuang, C., Hirota, S., Inanaga, K., Hashimoto, K., Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 136 (2015), 7–12.
39. Yao, W., Zhang, J.C., Ishima, T., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Suganuma, H., Ushida, Y., Yamamoto, M., Hashimoto, K., Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanine confers stress resilience in mice. Sci. Rep., 6, 2016, 30659.
40. Zhang, J.C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Wu, J., Ushida, Y., Suganuma, H., Hashimoto, K. Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. J. Nutri. Biochem. (in press), http://dx.doi.org/10.1016/j.jnutbio.2016.10.004.
41. Zhang, J.C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.X., Shirayama, Y., Hashimoto, K., Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int. J. Neuropsychopharmacol. 18 (2015), 1–12.
42. Zhang, J.C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Hashimoto, K., Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology 232 (2015), 4325–4335.
43. Zhang, J.C., Yao, W., Hashimoto, K., Brain-derived neurotrophic factor (BDNF) – TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr. Neuropharmacol. 14 (2016), 721–731.
44. Zheng, S., Laxmi, Y.R.S., David, E., Dinkova-Kostova, A.T., Shiavoni, K.H., Ren, Y., Zheng, Y., Trevino, I., Bumeister, R., Ojima, I., Wigley, W.C., Bliska, J.B., Mierke, D.F., Honda, T., Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents. J. Med. Chem. 55 (2012), 4837–4846.
45. Zhou, X., Keitner, G.I., Qin, B., Ravindran, A.V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., Xie, P., Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int. J. Neuropsychopharmacol., 18, 2015 pyv060.